Sindrom Turner

01Pathophysiology

Turner syndrome results from the complete or partial loss of one X chromosome in a phenotypic female. The single functioning X cannot fully compensate because certain genes on the X chromosome escape X-inactivation and require two copies for normal dosage. The most clinically relevant of these is the SHOX gene (Short stature HOmeoboX-containing) on the pseudoautosomal region of Xp. SHOX haploinsufficiency drives the short stature, cubitus valgus, short fourth metacarpal, and Madelung deformity that characterize the skeletal phenotype.

The gonadal dysgenesis is mechanistically distinct. Oogenesis requires two intact X chromosomes; with only one, primordial follicles undergo accelerated atresia in utero. By the time the patient reaches the age of puberty, the ovaries have already been replaced by fibrous tissue, the so-called streak ovaries. Because the gonads cannot produce estrogen, the hypothalamic-pituitary axis loses negative feedback, producing hypergonadotropic hypogonadism with markedly elevated FSH and LH. This is the mechanistic explanation for primary amenorrhea, lack of secondary sexual characteristics, and infertility.

The lymphatic abnormalities explain the most visually distinctive features. Defective lymphatic development in the fetus causes jugular lymphatic obstruction, producing cystic hygroma on prenatal ultrasound. When these dilated sacs eventually decompress, the redundant skin remains, manifesting postnatally as the webbed neck and low posterior hairline. Persistent lymphatic dysfunction in the periphery causes the puffy hands and feet that often prompt diagnosis in the newborn nursery.

The cardiovascular abnormalities are the most testable because they drive mortality. Aortic arch malformations are thought to result from in-utero distention of lymphatic channels compressing the aortic arch during development. The two highest-yield lesions are bicuspid aortic valve (most common, present in 30 percent) and coarctation of the aorta (present in 10 percent). Adults with Turner syndrome remain at lifelong risk for aortic root dilation and dissection, which is a leading cause of premature death.

02Classification and Clinical Manifestations

03Diagnostic Workup

The diagnostic pathway depends on the age at presentation. In the prenatal setting, suggestive ultrasound findings (cystic hygroma, increased nuchal translucency, coarctation, horseshoe kidney) prompt diagnostic chromosomal testing through chorionic villus sampling or amniocentesis. NIPT can suggest the diagnosis but is not confirmatory because of placental mosaicism and confined placental abnormalities. In the newborn, lymphedema of the hands and feet plus redundant nuchal skin is the classic trigger to send a karyotype.

In older children, the two most common entry points are unexplained short stature in a girl (height crossing percentiles downward, height below the 5th percentile, or height substantially below the midparental target) and delayed puberty or primary amenorrhea with elevated gonadotropins. A useful teaching rule: any girl with otherwise unexplained short stature deserves a karyotype, because the phenotype can be subtle in mosaic cases and 30 percent of patients are diagnosed only in adolescence or adulthood.

The best initial test for screening is therefore a directed clinical examination plus measurement of FSH (which will be elevated even before puberty in classic 45,X). The most accurate confirmatory test is the peripheral blood karyotype, counting at least 30 cells to detect low-level mosaicism. If clinical suspicion remains high despite a normal blood karyotype, additional tissue (skin fibroblasts) can be analyzed because mosaicism may be confined to gonadal tissue. FISH or chromosomal microarray is added to look for hidden Y-chromosome material, because patients with any Y material have a 15 to 30 percent risk of gonadoblastoma and require prophylactic gonadectomy.

Once the diagnosis is confirmed, every patient needs a baseline echocardiogram with cardiac MRI (because echo can miss aortic arch elongation and root dilation), renal ultrasound, thyroid panel, celiac screening, audiometry, and fasting glucose and lipid panel. These investigations are not optional; they form the diagnostic standard of care.

04Management and Treatment

The acute management priorities at diagnosis are: confirm the karyotype, evaluate the cardiovascular system, and screen for renal, thyroid, and celiac disease. The long-term management rests on three pillars: growth hormone for height, sequential estrogen then estrogen-progestin for puberty and bone health, and lifelong multisystem surveillance.

The "next best step" logic on examinations typically falls into one of these patterns. If the vignette shows a newborn with lymphedema and webbed neck, the next step is karyotype. If a girl with confirmed Turner syndrome has not yet had cardiac evaluation, the next step is echocardiogram with cardiac MRI. If a teenager with Turner syndrome is approaching pubertal age and has not yet entered puberty, the next step is low-dose estrogen therapy. If a Turner patient is planning pregnancy, the next step is comprehensive cardiac evaluation including aortic root measurement before conception.

Contraindications and cautions worth memorizing: growth hormone is contraindicated in active malignancy, severe scoliosis progression, and uncontrolled diabetes. Pregnancy in Turner syndrome carries a 100-fold increased risk of aortic dissection, so any aortic root dilation (indexed aortic size index above 2.0 to 2.5 cm/m²) is a relative contraindication to pregnancy. Estrogen should be started transdermally at a low dose and titrated slowly to mimic physiologic puberty; starting too early or too high compromises final adult height by accelerating epiphyseal closure.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The classic trap is mistaking Turner syndrome for Noonan syndrome when the vignette describes a webbed neck and congenital heart disease. The discriminators to lock in are sex (Turner is phenotypic female only, Noonan affects both sexes), karyotype (Turner has 45,X, Noonan is normal), and which side of the heart is involved (Turner equals left-sided lesions like bicuspid aortic valve and coarctation, Noonan equals right-sided lesions like pulmonic stenosis).

A second high-yield trap is dismissing a girl with isolated short stature as constitutional delay. The teaching point is that Turner syndrome can present with short stature as the only finding, particularly in mosaic forms, so the threshold to send a karyotype must be low. Bone age, FSH, and karyotype are the workup tools that separate these.

A third trap is the adolescent with primary amenorrhea. Test writers love to layer this presentation with subtle clues that point to one of three possible answers: Turner syndrome (short stature, elevated FSH, streak ovaries), androgen insensitivity (tall stature, breast development without pubic hair, 46,XY), or Mullerian agenesis (normal pubertal development, absent uterus, 46,XX). Reading the height, the breast and pubic hair status, and the FSH carefully tells you which one is being tested.

A fourth trap concerns pregnancy planning. Patients with Turner syndrome can conceive through donor oocyte IVF, but the question being tested is recognition of the catastrophic risk of aortic dissection. The correct answer for any Turner patient considering pregnancy is comprehensive cardiac evaluation with aortic root imaging before conception, not immediate referral for fertility treatment.

A fifth trap is the mosaic patient with hidden Y material. Any Turner patient found on FISH or microarray to have Y-chromosome material requires prophylactic gonadectomy because of the risk of gonadoblastoma. This is a common "next best step" question once the diagnosis is established.

The core competency being tested across Turner syndrome questions is pattern recognition across multiple organ systems combined with appropriate sequencing of confirmatory tests and multidisciplinary surveillance. Test writers reward the candidate who recognizes that short stature plus delayed puberty plus a left-sided cardiac lesion in a phenotypic female equals one diagnosis, that the confirmatory test is always karyotype, and that lifelong surveillance is what separates standard of care from inadequate management.